EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Navigating the Landscape of CMT1B: Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches

Mary Kate McCulloch, Fatemeh Mehryab, Afrooz Rashnonejad

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25179227 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mary Kate McCulloch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, 575 Children's Crossroad, Columbus, OH 43215, USA. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Disease Models, Animal, Genetic Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charcot Marie Tooth Research Foundation, Research Institute at Nationwide Children’s Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Charcot–Marie–Tooth type 1B (CMT1B) is a peripheral neuropathy caused by mutations in the gene encoding myelin protein zero (MPZ), a key component of the myelin sheath in Schwann cells. Mutations in the MPZ gene can lead to protein misfolding, unfolded protein response (UPR), endoplasmic reticulum (ER) stress, or protein mistrafficking. Despite significant progress in understanding the disease mechanisms, there is currently no effective treatment for CMT1B, with therapeutic strategies primarily focused on supportive care. Gene therapy represents a promising therapeutic approach for treating CMT1B. To develop a treatment and better design preclinical studies, an in-depth understanding of the pathophysiological mechanisms and animal models is essential. In this review, we present a comprehensive overview of the disease mechanisms, preclinical models, and recent advancements in therapeutic research for CMT1B, while also addressing the existing challenges in the field. This review aims to deepen the understanding of CMT1B and to encourage further research towards the development of effective treatments for CMT1B patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Charcot-Marie-Tooth DiseaseDisease Models, AnimalGenetic TherapyHumansAnimalsMutationMyelin P0 ProteinUnfolded Protein ResponseEndoplasmic Reticulum Stress

Stichwörter der Autor:innen

Charcot–Marie–Tooth type 1Bgene therapymyelin protein zeroneuropathyschwann cells

Substanzen

Myelin P0 ProteinMPZ protein, human

Autor:innen und Institutionen

  • Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, 575 Children's Crossroad, Columbus, OH 43215, USA.
  • Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA.

Förderung

  • Charcot Marie Tooth Research Foundation
  • Research Institute at Nationwide Children’s Hospital

Zitieren

APA

McCulloch, M. K., Mehryab, F., & Rashnonejad, A. (2024). Navigating the Landscape of CMT1B: Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179227

Vancouver

McCulloch MK, Mehryab F, Rashnonejad A. Navigating the Landscape of CMT1B: Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179227

BibTeX
@article{McCulloch2024,
  author = {McCulloch, Mary Kate and Mehryab, Fatemeh and Rashnonejad, Afrooz},
  title = {Navigating the Landscape of CMT1B: Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179227}
}
Kostenlos starten →